Joan Carles

Vall d'Hebron Hospital Universitari

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Vall d'Hebron Hospital Universitari

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Joan Carles has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

Joaquin Mateo
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
21 shared publications
Gisela Mir Arnau
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
19 shared publications
Julian Brandariz
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
19 shared publications
Victor Esquefa
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
19 shared publications
Andrea Bernardos
Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, 46022 Valencia, Spain
18 shared publications
Andrei Salca
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
18 shared publications

Latest Publications

Sort by

Website
Google Scholar
- 28 October 2026
- Published by Elsevier in The Lancet Oncology
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
by Steven M Yip, A Douglas Laird, Neeraj Agarwal, Stefanie Zschäbitz, Karim Fizazi, Nobuaki Matsubara, Jae Young Joung, Lawrence I Karsh, Joan Carles, André P Fay, et al.
Website
Google Scholar
- 28 October 2026
- Published by Elsevier in The Lancet Oncology
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
by Steven M Yip, A Douglas Laird, Neeraj Agarwal, Stefanie Zschäbitz, Karim Fizazi, Nobuaki Matsubara, Jae Young Joung, Lawrence I Karsh, Joan Carles, André P Fay, et al.
Open Access
Website
Google Scholar
- 14 October 2026
- Published by Springer Nature in Nature Medicine
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
by Francesca Zacchi, Elena Castro, Kathleen Imbach, Alejo Rodriguez-Vida, Sara Simonetti, Begoña Mellado, Gisela Mir Arnau, Daniel Aguilar, Daniel Castellano, Miguel Angel Climent, et al.
Website
Google Scholar
- 14 October 2026
- Published by Springer Nature in Nature Medicine
Open Access
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
by Francesca Zacchi, Elena Castro, Kathleen Imbach, Alejo Rodriguez-Vida, Sara Simonetti, Begoña Mellado, Gisela Mir Arnau, Daniel Aguilar, Daniel Castellano, Miguel Angel Climent, et al.
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Senolytic index (SI) values palbociclib
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S7 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Senolytic index (SI) values palbociclib
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Bubble plot analysis values for SASP signatures genes in abemaciclib- vs vehicle-treated prostate cancer cell lines
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Bubble plot analysis values for SASP signatures genes in abemaciclib- vs vehicle-treated prostate cancer cell lines
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Abemaciclib promotes cellular senescence in PC models in vivo
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Abemaciclib promotes cellular senescence in PC models in vivo
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Abemaciclib and palbociclib induce a senescent phenotype in PC models in vitro
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Abemaciclib and palbociclib induce a senescent phenotype in PC models in vitro
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Heatmap values for replisome genes in abemaciclib- vs vehicle-treated prostate cancer models
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S9 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Heatmap values for replisome genes in abemaciclib- vs vehicle-treated prostate cancer models
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Information for non-FDA-approved agents used in the study
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S10 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Information for non-FDA-approved agents used in the study
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
CDK4/6i-induced senescence is reversed after treatment withdrawal
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
CDK4/6i-induced senescence is reversed after treatment withdrawal
Open Access
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Senolytic index (SI) values abemaciclib
Website
Google Scholar
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
by Julian Brandariz, Lara de Llobet, Victor Esquefa, Daniel Aguilar, Andrei Salca, Sara Arce-Gallego, Pablo Cresta Morgado, Arnau Sole, Laura Agundez, Gisela Mir, et al.
Senolytic index (SI) values abemaciclib

Show all